Dosing strategy of intrapleural bortezomib for myelomatous pleural effusion: A case report and review of literature
Abstract Myelomatous pleural effusion (MPE) is a rare, often treatment‐resistant complication of multiple myeloma. Intrapleural bortezomib shows promise but lacks standardized dosing. We report a 62‐year‐old woman with MPE treated with 1.3 mg/m2 (2 mg) subcutaneous and 0.975 mg/m2 (1.5 mg) intrapleu...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.998 |